This educational webinar was presented on March 28th, 2022, and was co-hosted by the ACPMP Research Foundation and patient advocate, Chrissy Buttigieg.
This meeting was free to all!
Topics covered during the educational webinar included:
- What is the risk and benefit of CRS?
- What is EPIC and how does it differ from HIPEC?
- Does IPC improve outcomes?
- What is the current standing of the ICARuS trial?
About Dr. Nash
Garrett M Nash, MD, MPH, FACS, FASCRS, FSSO is a Vice Chair of the Department of Surgery at Memorial Sloan Kettering (MSK) in New York City. He is board certified in Surgery and Colorectal Surgery. He was born and was raised in Ireland and moved to the United States where he received an AB from Brown University in 1994, an MD from Columbia University, College of Physicians and Surgeons in 1998, and an MPH from Harvard School of Public Health in 2009. He completed his Surgery Residency at New York Presbyterian/Cornell and Colorectal Surgery Fellowship at New York Presbyterian Cornell/Columbia. He completed an additional fellowship in Advanced Colorectal Surgical Oncology at MSK. His practice includes regional therapy for colorectal and peritoneal cancers including appendix cancer and mesothelioma and robotic surgery for colorectal cancer. His primary research focus is clinical trials of regional therapy and has multiple research collaborations with medical oncology and nuclear medicine studying mechanisms of tumor metastases and progression and developing novel regional therapies. He is the primary investigator of ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery), a randomized clinical trial studying the efficacy of intraperitoneal therapy for colon and appendix cancer. He has authored papers on a variety of subjects including cytoreductive surgery, intraperitoneal chemotherapy, minimally invasive surgery, sphincter-sparing rectal surgery, and predictors of outcome following surgery. He has chaired the Awards Committee and is Vice Chair of the Conflict of Interest Committee of the American Society of Colon and Rectal Surgeons. At MSK, he is the Chair of the Surgical Quality Assurance Committee, Surgeon Champion for the Patient and Family Advisory Council for Quality (PFACQ), a member of Research Council, the Chair of the Complex General Surgical Oncology Fellowship Clinical Competence Committee, the Program Director of the Advanced Colorectal Surgical Oncology Fellowship, and the Site Director of the Colon and Rectal Surgery Residency, shared with the New York Presbyterian Hospital.